Advertisement
Advertisement
U.S. markets close in 4 hours 49 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Astellas Pharma Inc. (4503.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
1,866.00+33.50 (+1.83%)
At close: 03:15PM JST
Advertisement

  • Dividend

    4503.T announced a cash dividend of 30.00 with an ex-date of Mar. 30, 2023

Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close1,832.50
Open1,847.00
Bid1,865.50 x 0
Ask1,870.50 x 0
Day's Range1,840.50 - 1,871.50
52 Week Range1,823.50 - 2,205.00
Volume6,902,900
Avg. Volume5,375,179
Market Cap3.399T
Beta (5Y Monthly)0.55
PE Ratio (TTM)24.90
EPS (TTM)74.95
Earnings DateApr 25, 2023 - May 01, 2023
Forward Dividend & Yield60.00 (3.27%)
Ex-Dividend DateMar 30, 2023
1y Target Est2,636.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 4503.T

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      US declines to force lower price on cancer drug Xtandi

      The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency "march-in" authority, the National Institutes of Health (NIH) said on Tuesday. Xtandi's wholesale cost is between $160,000-$180,000 per patient a year. Patient group the Union for Affordable Cancer Treatment first filed a petition calling on the NIH to use its authority to lower the drug's price in March 2016.

    • PR Newswire

      Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

      Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present detailed results from the Phase 3 GLOW trial evaluating first-line treatment with zolbetuximab, an investigational first-in-class Claudin 18.2 (CLDN18.2) targeted monoclonal antibody, plus CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin) versus placebo plus CAPOX in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gast

    • Benzinga

      Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug

      https://cdn.benzinga.com/files/images/story/2023/03/17/pfe.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Pfizer Inc (NYSE: PFE) and Astellas Pharma Inc (OTC: ALPMY) released topline results from the Phase 3 EMBARK trial evaluating Xtandi (enzalutamide) in non-metastatic hormone-sensitive prostate cancer. The FDA first approved Xtandi in 2012 for castration-resistant prostate cancer (CRPC), who had previously received docetaxel and was granted approval in 2014 for chemotherapy-naïve men wit

    Advertisement
    Advertisement